224.03 USD
↘ 3.25 (1.43%)AT CLOSE (03:59 PM EDT)
Alnylam Pharmaceuticals, Inc.
ALNYNASDAQ • USD
226.08
↗ 2.05 (0.91%)
POST MARKET (AS OF 07:57 PM EDT)
Post Market
AS OF 07:57 PM EDT
226.08
↗ 2.05 (0.91%)
Market: CLOSED
Alnylam Pharmaceuticals, Inc. (ALNY) trades at $224.03 per share. There is a divergence between signals — underlying fundamentals rate "Buy" but technical indicators lean "Strong Sell". This is driven by a robust Altman Z-Score, exceptional Return on Equity (59.7%), a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation front, ALNY trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Oct 23, 2026.
Open?$227.28
High?$229.39
Low?$222.00
Prev. Close?$227.28
Volume?1.0M
Avg. Volume?1.3M
VWAP?$225.18
Rel. Volume?0.78x
Bid / Ask
Bid?$220.00 × 40
Ask?$232.15 × 120
Spread?$12.15
Midpoint?$226.08
Valuation & Ratios
Market Cap?30.0B
Shares Out?133.8M
Float?133.6M
Float %?99.9%
P/E Ratio?37.10
P/B Ratio?22.14
EPS?$6.04
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Themes
Employees
2.5K
Market Cap
30.0B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2004-05-28
Address
675 WEST KENDALL STREET
CAMBRIDGE, MA 02142
Phone: (617) 551-8200
CAMBRIDGE, MA 02142
Phone: (617) 551-8200
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookBuy
Strong SellNeutralStrong Buy
F-Score?60
Z-Score?97
Momentum?62
Short Sent.?57
Piotroski F-Score?5/9Mixed
Altman Z-Score?4.81Safe
Confidence?73%Moderate
Short InterestHigh
Short % of Float?5.77%Elevated
Short Interest?7.7M
Days to Cover?6.5
Free Float133.6M
Avg Daily Volume1.2M
Settlement Date2026-09-30
Financial Health
Current Ratio?3.05Strong
Quick Ratio?2.99Strong
Cash Ratio?1.13Strong
Debt/Equity?0.75Moderate
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score39/100
P/E?37.1PRICEY▾
Peers100
S&P19
P/B?22.14HIGH▾
Peers100
S&P6
P/S?6.24FAIR▾
Peers100
S&P20
P/FCF?37.8PRICEY▾
Peers100
S&P19
EV/EBITDA?27.8HIGH▾
Peers100
S&P12
EV/Sales?6.09HIGH▾
Peers100
S&P27
Returns & Efficiency
ROE?59.7%STRONG▾
Peers50
S&P93
ROA?14.5%STRONG▾
Peers50
S&P86
Cash Flow & Enterprise
FCF?$793.9M
Enterprise Value?$29.3B
Fundamentals ratios updated end of day